Sandoz Group AG Cash Flow Conversion Efficiency
Sandoz Group AG cash flow conversion efficiency. Based on the latest financial reports, Sandoz Group AG (SDZ) has a cash flow conversion efficiency ratio of 0.094x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF851.94 Million ≈ $1.08 Billion USD) by net assets (CHF9.03 Billion ≈ $11.41 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sandoz Group AG (2020–2025)
Cash flow conversion efficiency of Sandoz Group AG from 2020 to 2025. This chart illustrates how Sandoz Group AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sandoz Group AG stock quote for real-time trading data and today's change.
Sandoz Group AG Cash Flow Conversion Ratio Explained
Sandoz Group AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sandoz Group AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sandoz Group AG ranked by their cash flow conversion efficiency. Also see Sandoz Group AG (SDZ) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.208x |
|
Atmos Energy Corporation
NYSE:ATO
|
0.025x |
|
Teledyne Technologies Incorporated
NYSE:TDY
|
0.022x |
|
Hannover Rück SE
F:HNR1
|
0.128x |
|
KONE Oyj
HE:KNEBV
|
0.129x |
|
DexCom Inc
NASDAQ:DXCM
|
0.178x |
|
Jabil Circuit Inc
NYSE:JBL
|
0.403x |
|
Heidelberg Materials AG
XETRA:HEI
|
0.169x |
Annual Cash Flow Conversion Efficiency for Sandoz Group AG (2020–2025)
The table below shows the annual cash flow conversion efficiency of Sandoz Group AG from 2020 to 2025. Review Sandoz Group AG free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF9.38 Billion ≈ $11.87 Billion |
CHF1.59 Billion ≈ $2.02 Billion |
0.170x | +111.37% |
| 2024-12-31 | CHF8.16 Billion ≈ $10.32 Billion |
CHF656.00 Million ≈ $829.36 Million |
0.080x | +113.76% |
| 2023-12-31 | CHF8.65 Billion ≈ $10.94 Billion |
CHF325.31 Million ≈ $411.28 Million |
0.038x | -100.00% |
| 2022-12-31 | CHF77.14K ≈ $97.52K |
CHF1.17 Billion ≈ $1.48 Billion |
15142.076x | +9097643.39% |
| 2021-12-31 | CHF7.44 Billion ≈ $9.40 Billion |
CHF1.24 Billion ≈ $1.57 Billion |
0.166x | +10.25% |
| 2020-12-31 | CHF6.83 Billion ≈ $8.63 Billion |
CHF1.03 Billion ≈ $1.30 Billion |
0.151x | -- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more